Taofeek Owonikoko MD, PhD, MSCR - Lurbinectedin, a potential practice changing drug if approved

Taofeek Owonikoko MD, PhD, MSCR - Lurbinectedin, a potential practice changing drug if approved

PharmaMar

7 months
48 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Lurbinectedin, a potential practice changing drug if approved, will be the only agent available in SCLC tested with immunotherapy. PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA.

 

 

 

 

lurbinectedin, potential practice changing drug, new drug application (nda), nda, pharmamar, immunotherapy, sclc

Up Next Autoplay